Jade Biosciences (NASDAQ:JBIO) Stock Price Up 7.9% - Time to Buy?

Key Points

• Jade Biosciences shares rose 7.9% to approximately $14.93, although trading volume was 66% below the average session volume.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $51.75, despite ratings ranging from “Strong Sell” to “Buy.”
• The clinical-stage biotech reported a quarterly EPS loss of $0.76, missing estimates by $0.10, and analysts expect a full-year loss of $2.89 per share; its drug candidates remain subject to clinical and regulatory risks.

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) traded up 7.9% during trading on Tuesday. The stock traded as high as $14.75 and last traded at $14.9250. 257,017 shares were traded during mid-day trading, a decline of 66% from the average session volume of 765,068 shares. The stock had previously closed at $13.83.

Analyst Ratings Changes

A number of analysts have commented on JBIO shares. Wall Street Zen cut shares of Jade Biosciences from a "sell" rating to a "strong sell" rating in a research note on Saturday, September 12th. Wedbush reissued an "outperform" rating and issued a $47.00 price objective on shares of Jade Biosciences in a research note on Thursday, October 1st. BTIG Research upped their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Jefferies Financial Group reissued a "buy" rating and set a $48.00 target price on shares of Jade Biosciences in a research note on Tuesday, August 11th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of Jade Biosciences in a research note on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $51.75.

Jade Biosciences Stock Performance

The firm has a market capitalization of $935.81 million, a P/E ratio of -7.67 and a beta of 1.64. The firm has a 50-day moving average of $17.95 and a 200-day moving average of $19.74.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Equities analysts anticipate that Jade Biosciences, Inc. will post -2.89 EPS for the current fiscal year.

Institutional Trading of Jade Biosciences

A number of large investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in shares of Jade Biosciences in the 1st quarter worth approximately $43,557,000. Stempoint Capital LP bought a new position in Jade Biosciences during the first quarter worth $2,164,000. Bank of New York Mellon Corp acquired a new stake in shares of Jade Biosciences in the 2nd quarter worth about $1,896,000. Renaissance Technologies LLC raised its holdings in Jade Biosciences by 94.0% during the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company's stock worth $1,897,000 after purchasing an additional 65,438 shares in the last quarter. Finally, Corient Private Wealth LP purchased a new stake in Jade Biosciences during the second quarter valued at about $1,367,000.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company's research and development efforts are directed toward antibody-based medicines designed to address significant unmet needs in immune-mediated conditions.

Jade's pipeline includes investigational therapeutic programs intended to modulate biological pathways involved in inflammation and immune-system activity. As a development-stage company, its products remain subject to clinical testing and regulatory review, and there is no assurance that any candidate will receive approval or reach the commercial market.

The company is headquartered in the United States and is developing its portfolio for potential use in global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.